CF102 for the treatment of hepatocellular carcinoma: A phase I/II, open-label, dose-escalation study.
Salomon M. Stemmer
Stock Ownership - Can-Fite BioPharma
Ofer Benjaminov
No relevant relationships to disclose
Gal Medalia
No relevant relationships to disclose
Noa Ciuraru
No relevant relationships to disclose
Michael H. Silverman
Consultant or Advisory Role - Can Fite BioPharma
Stock Ownership - Can Fite BioPharma
Sara Bar Yehuda
Stock Ownership - Can Fite BioPharma
Sari Fishman
Employment or Leadership Position - Can Fite BioPharma
Stock Ownership - Can Fite BioPharma
Zivit Harpaz
Employment or Leadership Position - Can Fite BioPharma
Stock Ownership - Can Fite BioPharma
Motti Farbstein
Employment or Leadership Position - Can Fite BioPharma
Stock Ownership - Can Fite BioPharma
Shira Cohen
Employment or Leadership Position - Can Fite BioPharma
Stock Ownership - Can Fite BioPharma
Renana Petoka
Employment or Leadership Position - Can Fite BioPharma
Stock Ownership - Can Fite BioPharma
Barak Singer
Employment or Leadership Position - Can Fite BioPharma
Stock Ownership - Can Fite BioPharma
William D Kerns
Consultant or Advisory Role - Can Fite BioPharma
Stock Ownership - Can Fite BioPharma
Pnina Fishman
Employment or Leadership Position - Can Fite BioPharma
Stock Ownership - Can Fite BioPharma